|Trade names||Camoquin, others|
|(what is this?)|
Artesunate/amodiaquine, sold under the trade name Camoquin among others, is a medication used for the treatment of malaria. It is a fixed-dose combination of artesunate and amodiaquine. Specifically it recommended for acute uncomplicated Plasmodium falciparum malaria. It is taken by mouth.
Common side effects include loss of appetite, nausea, abdominal pain, sleepiness, trouble sleeping, and cough. Safety in pregnancy is not clear; however, the medication may be used if others are not possible. It is believed to be safe for use during breastfeeding. Artesunate and amodiaquine are both antimalarial medication; however, work by different mechanisms.
Artesunate/amodiaquine was commercially launched in 2007. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. Artesunate/amodiaquine is available as a generic medication. The wholesale cost in the developing world is about 0.85 to 1.52 USD for a course of treatment. As of 2014 it is not commercially available in the United States or United Kingdom.
Early clinical trials showed that a once-a-day dosage was effective. It was subsequently clinically shown to be equally effective as artemether/lumefantrine, although it is likely to be more effective in the field due to its simpler once-a-day dosage compared to artemether/lumefantrine twice-per-day dosage.
Society and culture
- Ainsworth, Sean B. (2014). Neonatal Formulary: Drug Use in Pregnancy and the First Year of Life. John Wiley & Sons. p. 75. ISBN 9781118819517. Archived from the original on 2016-12-20.
- The selection and use of essential medicines: Twentieth report of the WHO Expert Committee 2015 (including 19th WHO Model List of Essential Medicines and 5th WHO Model List of Essential Medicines for Children). (PDF). WHO. 2015. p. 435. ISBN 9789240694941. Archived (PDF) from the original on 20 December 2016. Retrieved 8 December 2016.
- WHO Model Formulary 2008 (PDF). World Health Organization. 2009. p. 187. ISBN 9789241547659. Archived (PDF) from the original on 13 December 2016. Retrieved 8 December 2016.
- "Artesunate + Amodiaquine". International Drug Price Indicator Guide. Retrieved 8 December 2016.
- "Artesunate Amodiaquine Winthrop" (PDF). WIPO. August 2010. Archived (PDF) from the original on 24 October 2016. Retrieved 12 December 2016.
- "New, Once-a-Day Fixed-Dose Combination Against Malaria Now Available – DNDi". www.dndi.org. 1 March 2007. Archived from the original on 20 December 2016. Retrieved 12 December 2016.
- "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Archived (PDF) from the original on 13 December 2016. Retrieved 8 December 2016.
- Goldman, Lee; Schafer, Andrew I. (2015). Goldman-Cecil Medicine. Elsevier Health Sciences. p. 2112. ISBN 9780323322850. Archived from the original on 2016-12-20.
- Ndiaye, Jean; Randrianarivelojosia, Milijaona; Sagara, Issaka; Brasseur, Philippe; Ndiaye, Ibrahima; Faye, Babacar; Randrianasolo, Laurence; Ratsimbasoa, Arsène; Forlemu, Doris; Moor, Vicky; Traore, Aminata; Dicko, Yahia; Dara, Niawanlou; Lameyre, Valérie; Diallo, Mouctar; Djimde, Abdoulaye; Same-Ekobo, Albert; Gaye, Oumar (June 2009). "Randomized, multicentre assessment of the efficacy and safety of ASAQ – a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria". Malaria Journal. 8: 125. PMC . PMID 19505304. doi:10.1186/1475-2875-8-125. Archived from the original on 19 September 2011. Retrieved 18 January 2013.
- Nidiaye, Jean-Louis A; Faye, Babacar; Gueye, Ali; Tine, Roger; Ndiaye, Daouda; Tchania, Corinne; Ndiaye, Ibrahima; Barry, Aichatou; Cissé, Badara; Lameyre, Valérie; Gaye, Oumar (2011). "Repeated treatment of recurrent uncomplicated Plasmodium falciparum malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: a randomized, open-label trial". Malaria Journal. 10: 237. PMC . PMID 21838909. doi:10.1186/1475-2875-10-237. Archived from the original on 10 October 2014. Retrieved 18 January 2013.
|This antiinfective drug article is a stub. You can help Wikipedia by expanding it.|